SAT0529 PROLONGED TNF-INHIBITOR TREATMENT DURATION IS ASSOCIATED WITH LOWER RISK OF HAND OSTEOARTHRITIS PROGRESSION IN PATIENTS WITH RECENT-ONSET RHEUMATOID ARTHRITIS AFTER 10-YEAR FOLLOW-UP
Background: Increasing evidence indicates involvement of the pro-inflammatory cytokine TNF-α in hand osteoarthritis (OA) pathogenesis. Ten years clinical and radiologic follow-up of the BeSt study, a randomized trial primarily designed to investigate targeted treatment in rheumatoid arthritis (RA) patients, offered the unique opportunity to study the long-term effects of TNF inhibitors (TNFi) on the development and progression of hand OA. The distal interphalangeal joints (DIPs) are rarely affected in RA, which allowed to evaluate primary OA separately. Objectives: To investigate the effect of TNFi on incidental and progressive radiographic hand OA after 10-year follow-up in recent-onset RA patients. Methods: At baseline and 10-year follow-up 262 patients (mean age 52 years, 66% women) were available for radiologic assessment of hand OA. Eighteen interphalangeal joints (IPs) were scored for osteophytes (OP) using the Osteoarthritis Research Society International (OARSI) atlas (0-3; summated score 0-54), and according to the Kellgren-Lawrence (KL) scoring method (0-4; summated score 0-72). Incidental OA was defined as an increase ≥1 in summated OP score or ≥2 in summated KL score in absence of OA at baseline, and progressive OA as an increase ≥3 in summated OP or KL score in presence of OA at baseline, based on the smallest detectable change. TNFi treatment and disease activity score (DAS) were assessed on standardized visits at a three-monthly interval. Associations between duration of TNFi treatment in months and incidental and progressive OA were analyzed using generalized linear models with Poisson distribution and robust standard errors, while adjusting for age, gender, time averaged DAS, time averaged Sharp-van der Heijde score and hand OA severity at baseline. Results: Based on the OP score, 126 patients (48%) were classified with OA at baseline in the DIPs and 82 patients (31%) in the proximal IPs (PIPs). Incidental OA developed in 33% of patients in DIPs and in 42% in PIPs. Progressive OA occurred in 30% of patients in DIPs and in 38% in PIPs. Of patients with and without OA at baseline, irrespective of joint location, 63% and 55% were treated with TNFi, with a median treatment duration of 47 and 36 months, respectively. 
Background:
We have previously shown that people suffering with chronic pain in hand OA have activation of central brain pain processing centres localised to the anterior cingulate cortex, insular cortex and thalamus by functional neuroimaging (1) and algometry (2). Objectives: We hypothesised that hand OA subjects will have structural differences in 3 pain-processing regions of the brain -the anterior cingulate cortex (ACC), insular cortex and thalamus -based on activation of brain centres we have found previously (1). Our brain neuroimaging work was part of a randomised, placebo-controlled trial to assess the effect on clinical pain outcomes by intervention with centrally-acting analgesic agents: pregabalin or duloxetine. Methods: The primary outcome measures for our clinical trial were hand pain Numerical Rating Scale (NRS) and AUSCAN pain after 12 weeks' treatment. In secondary outcome analyses, participants with hand OA (n=28) underwent T1-weighted MRI of the brain before and after 12 weeks of treatment with pregabalin, duloxetine or placebo therapy. Grey matter brain structure was compared using FreeSurfer regional volumetric analysis and voxel-based morphometry (VBM) to age-matched controls (n=11), and evaluated for volume changes in the ACC, insular cortex and thalamus. Results: In our clinical trial, we observed clinically significant improvement in pregabalin, duloxetine and placebo treatment groups after 12 weeks (ANOVA p=0.0078). Most notably, pairwise comparisons for pregabalin vs placebo showed significant improvement for NRS pain and AUSCAN pain outcomes in the ITT analysis (p<0.05), but not for duloxetine vs placebo after 12 weeks' (p>0.05). Both voxel-wise and regional volumetric analyses demonstrated areas of reduced grey matter volume in the ACC of hand OA subjects, relative to control subjects, at baseline (p<0.05) (Figure 1 ). The structural differences in the ACC persisted following 12 weeks of treatment with pregabalin, duloxetine or placebo therapy (p<0.05). We did not observe structural differences in the insular cortex or thalamus in any of the three groups.
Conclusions:
We found that the ACC volume was reduced in participants with hand OA. The ACC is a key pain-processing region of the brain. Changes in ACC grey matter volume have previously been described in other painful conditions, but not hand OA. ACC grey matter volume reduction is thought to represent neural plasticity in chronic pain states. Our data supports the role of central sensitisation in hand OA and provides a rationale for the further investigation of centrallyacting analgesics in its management. Our trial demonstrated improvement in clinical endpoints for pain for pregabalin vs placebo and duloxetine vs placebo, respectively (p<0.05). However, structural differences in the ACC were still evident following 12 weeks of treatment with pregabalin or duloxetine. This may relate to the relatively short duration of treatment in our study. Alternatively, the baseline differences in the ACC may represent irreversible changes. Longitudinal studies with greater follow-up periods are necessary to further investigate this.
